Arsenic Trioxide Compound Modulates Multiple Myeloma Phenotypes: Assessment on Cell Line Models

Recent evidences suggest that multiple myeloma phenotypes (mmps) are involved in the infiltration of multiple myelomaaffectedmarrow foci. in this study, the effects of arsenic trioxide on the invasive and angiogenic phenotypes of multiplemyeloma (mm) cell line were assessed on a dose-response and time-course basis. multiple myeloma cell line, karpas 707,was treated with step-wise elevated concentrations of arsenic trioxide compound at 24, 48, and 72 h intervals. cytotoxicitywas assessed with a colorimetric assay. potential antiinvasive phenotype was analyzed with mmp-2 zymography. to verifydirectly the anti angiogenic effect, f1 endothelial cell line was also treated with arsenic and the dose-dependent cytotoxicitywas assessed with a colorimetric assay. apoptotic properties of arsenic trioxide compound were investigated using tunelassay. the significant dose-dependent inhibitory effects of arsenic trioxide on mmp-2 were seen at given concentrations.cytotoxicity analysis revealed much higher cell death than untreated cells (p< 0.01), both in karpas 707 and f1 endothelialcell lines. colectively, this study showed that arsenic trioxide might potentially elicit anti-invasive anti-angiogenesis propertiesin the treatment of myeloma dissemination process. in addition, the concurrent inhibition of mmps activity and endothelialcell proliferation could compose the scenario of neoangiogenesis inhibition in the marrow-infiltrated foci.